Artificial Intelligence (AI) in Respiratory Diseases Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The artificial intelligence (AI) in respiratory diseases market size has grown strongly in recent years. It will grow from $7.66 billion in 2024 to $8.05 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to increasing government regulations, growing environmental concerns, increasing aging population, growing patient-centric healthcare approaches, rise in healthcare infrastructure development.

The artificial intelligence (AI) in respiratory diseases market size is expected to see strong growth in the next few years. It will grow to $9.85 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing prevalence of respiratory diseases, rising need for early detection and diagnosis, growing environmental pollution, rising healthcare expenditure, research and development initiatives. Major trends in the forecast period include technological advancements, drug discovery and development, personalized treatment plans, telemedicine and remote patient monitoring, remote patient monitoring.

Growing environmental pollution is expected to significantly drive the growth of artificial intelligence (AI) in the respiratory disease market in the coming years. Environmental pollution, including the release of harmful substances and energy into the environment, contributes to various respiratory health issues. AI has the potential to mitigate the impact of environmental pollution on respiratory health through real-time monitoring, personalized risk assessments, and advanced decision-making tools. For instance, according to the US Energy Information Administration, CO2 emissions increased from 35.72 billion metric tons in 2021 to 38.5 billion metric tons in 2022, underscoring the rising environmental pollution levels. As the effects of pollution on respiratory health intensify, the adoption of AI in the respiratory disease market is expected to accelerate, enabling better management and prevention of pollution-related health risks.

Key players in the artificial intelligence (AI) segment of the respiratory diseases market are innovating with products such as N-Tidal devices designed to monitor patients' tidal breathing patterns. The N-Tidal device measures the volume of air exchanged during normal breathing, providing crucial insights into lung function. For instance, in August 2023, TidalSense, a UK-based respiratory technology company, introduced N-Tidal, an AI-regulated technology tailored for the diagnosis and management of chronic obstructive pulmonary disease (COPD). This technology integrates N-Tidal's CO2 sensor data with an AI platform to track changes in lung function, enhancing COPD diagnosis and management. Clinical studies have demonstrated the technology's high accuracy, promising to revolutionize the diagnostic process for respiratory ailments. The launch represents a significant milestone in leveraging AI for respiratory disease assessment, offering a more convenient and efficient alternative to traditional diagnostic methodologies.

In July 2023, ResMed Inc., a prominent US-based medical equipment provider renowned for its cloud-connectable medical devices, finalized the acquisition of Somnoware for an undisclosed sum. This strategic move bolsters ResMed's portfolio in sleep and respiratory care while synergizing with its current suite of digital respiratory healthcare solutions. The acquisition is poised to elevate patient care by optimizing the management of patient data, streamlining equipment ordering, scheduling appointments, and monitoring compliance. Ultimately, these enhancements are expected to elevate patient experience and health outcomes. Somnoware, a US-based cloud platform, specializes in advanced respiratory care management and hospital-at-home solutions, aligning seamlessly with ResMed's commitment to innovation and excellence in healthcare.

Major companies operating in the artificial intelligence (AI) in respiratory diseases market report are Siemens Healthineers, Philips Healthcare, General Electric (GE) Healthcare, Verily Life Sciences LLC, DeepMind Health, Merative L.P., Innovaccer, Freenome, Aidoc Medical, Butterfly Network, Infervision, Imagen Technologies, Caption Health, Gauss Surgical Inc., Swaasa AI, Inspirata Inc., VIDA Diagnostics Inc., Enlitic, Thirona B.v., ArtiQ, Icometrix, Zynnon AG, Aidence, Arterys, Dectrocel Healthcare, PneumoWave Ltd.

North America was the largest region in the artificial Intelligence (AI) in respiratory diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (ai) in respiratory diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (ai) in respiratory diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial Intelligence (AI) in respiratory diseases market includes revenues earned by entities by providing services such as AI-assisted imaging analysis, digital pathology platforms, and AI-powered rehabilitation programs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The AI in respiratory diseases market also includes sales IoT devices, wearables, and smart inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Artificial intelligence (AI) in the context of respiratory diseases involves leveraging AI and machine learning techniques to assist healthcare professionals in diagnosing, managing, and treating various respiratory conditions. This technology holds significant potential across pulmonary medicine, offering applications in image analysis, predictive modeling, and disease management.

The primary imaging modalities in artificial intelligence (AI) for respiratory diseases include magnetic resonance imaging (MRI), computed tomography (CT) scans, and electronic patient-reported outcomes (ePRO). In the realm of chronic obstructive pulmonary disease (COPD), AI is applied to aid in the diagnosis, management, and treatment of this condition. Its applications extend to various indications such as chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary infections. These AI technologies find utilization in diverse healthcare settings, including hospitals, diagnostic centers, ambulatory surgical centers, and other medical facilities.

The artificial intelligence (AI) respiratory disease market research report is one of a series of new reports that provides artificial intelligence (AI) respiratory disease market statistics, including artificial intelligence (AI) respiratory disease industry global market size, regional shares, competitors with an artificial intelligence (AI) respiratory disease market share, detailed artificial intelligence (AI) respiratory disease market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) respiratory disease industry. This artificial intelligence (AI) respiratory disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.